Zobrazeno 1 - 10
of 1 700
pro vyhledávání: '"Inhibitor resistance"'
Autor:
Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova-Todorova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 8, Pp 1957-1980 (2024)
Abstract Acquired resistance to PARP inhibitors (PARPi) remains a treatment challenge for BRCA1/2-mutant breast cancer that drastically shortens patient survival. Although several resistance mechanisms have been identified, none have been successfull
Externí odkaz:
https://doaj.org/article/2b7acab7d8864163a88c5615d51c25ce
Autor:
Chuhong Hu, Yvyin Zhang, Jie Yang, Yanli Xu, Tingfen Deng, Yumiao Li, Shilin Xu, Shunqing Wang, Peihong Wang
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is a common mutation type in acute myeloid leukemia (AML) and is usually associated with poor patient prognosis. With advancements in molecular diagnostics and the
Externí odkaz:
https://doaj.org/article/8009670eecd249c4ad38edcc32956240
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The KRAS protein, a product of the KRAS gene (V-ki-ras2 Kirsten rat sarcoma viral oncogene homolog), functions as a small GTPase that alternates between an active GTP-bound state (KRAS(ON)) and an inactive GDP-bound state (KRAS(OFF)). The KRASG12C mu
Externí odkaz:
https://doaj.org/article/1055145bf0da40a7975e74cc2ae8ad35
Autor:
Su Yin Lim, Yingxin Lin, Jenny H. Lee, Bernadette Pedersen, Ashleigh Stewart, Richard A. Scolyer, Georgina V. Long, Jean Y.H. Yang, Helen Rizos
Publikováno v:
EBioMedicine, Vol 107, Iss , Pp 105308- (2024)
Summary: Background: Melanoma is a heterogeneous cancer influenced by the plasticity of melanoma cells and their dynamic adaptations to microenvironmental cues. Melanoma cells transition between well-defined transcriptional cell states that impact tr
Externí odkaz:
https://doaj.org/article/0f6bc570850d4b089ffba99d3b6434f7
Publikováno v:
Annals of Medicine, Vol 56, Iss 1 (2024)
AbstractAURKA is a threonine or serine kinase that needs to be activated by TPX2, Bora and other factors. AURKA is located on chromosome 20 and is amplified or overexpressed in many human cancers, such as breast cancer. AURKA regulates some basic cel
Externí odkaz:
https://doaj.org/article/00f2d0b5028640689f0c6c991d90aad5
Publikováno v:
Medicine in Novel Technology and Devices, Vol 22, Iss , Pp 100295- (2024)
Exploring novel therapeutic targets of Diffuse large B cell lymphoma (DLBCL) to overcome its resistance to Bruton's Tyrosine Kinase (BTK) inhibitors is a key topic. Lipid metabolism, crucial in the resistance landscape of various cancers, may unlock
Externí odkaz:
https://doaj.org/article/0491323f5c874a1c8334b630333f19b2
Autor:
Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-26 (2023)
Abstract Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably t
Externí odkaz:
https://doaj.org/article/b1e55395cfef45b29bb14f52778076da
Autor:
Robert Hsu, David J. Benjamin
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
In the past 15 years, non-small cell lung cancer (NSCLC) treatment has changed with the discovery of mutations and the development of new targeted therapies and immune checkpoint inhibitors. Epidermal growth factor receptor (EGFR) was the first mutat
Externí odkaz:
https://doaj.org/article/4145f65a24604133babc19ca3930e8b6
Autor:
Aypara Hasanova, Chingiz Asadov, Nigar Karimova, Aytan Shirinova, Gunay Aliyeva, Zohra Alimirzoyeva
Publikováno v:
Pathology and Oncology Research, Vol 29 (2023)
Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Here, we present the first report of the spectrum of mutations in the BCR-ABL
Externí odkaz:
https://doaj.org/article/ad664eb81df5488ca2e95a1c659f0f90
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.